Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1995-3-14
|
| pubmed:abstractText |
Anemia is common in cancer patients and may require treatment for symptomatic palliation. Transfusion has been the mainstay of therapy, but is not without risk. Because erythropoietin levels in cancer-related anemia are inadequate for the degree of anemia, recombinant human erythropoietin has been studied to treat the anemia. Results from these studies are encouraging.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0889-8588
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
961-73
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7852218-Anemia,
pubmed-meshheading:7852218-Blood Transfusion,
pubmed-meshheading:7852218-Clinical Trials as Topic,
pubmed-meshheading:7852218-Combined Modality Therapy,
pubmed-meshheading:7852218-Cost-Benefit Analysis,
pubmed-meshheading:7852218-Erythropoietin,
pubmed-meshheading:7852218-Humans,
pubmed-meshheading:7852218-Neoplasms,
pubmed-meshheading:7852218-Recombinant Proteins
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Clinical application of recombinant erythropoietin in anemic cancer patients.
|
| pubmed:affiliation |
Department of Medicine, University of Pennsylvania School of Medicine, Graduate Hospital Division of Hematology/Oncology, Philadelphia.
|
| pubmed:publicationType |
Journal Article
|